Paragon BioTeck, Inc., Announces FDA Acceptance and Priority Review Designation of New Drug Application

Phenylephrine, Press Release

TIGARD, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, […]

Read More